Drug Trial Radar · NCT07215260
A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body
Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Nov 5, 2025
Primary completion
Dec 7, 2025
Study completion Dec 18, 2025
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Oct 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this trial is to assess the effect of BI 3000202 on the pharmacokinetics of rosuvastatin and digoxin given as a cocktail.
Conditions
- Healthy
Interventions
BI 3000202Drug
BI 3000202
RosuvastatinDrug
Rosuvastatin
DigoxinDrug
Digoxin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)Time frame: Up to Day 7
- Area under the concentration-time curve of digoxin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)Time frame: Up to Day 7
- Maximum measured concentration of rosuvastatin in plasma (Cmax)Time frame: Up to Day 7
- Maximum measured concentration of digoxin in plasma (Cmax)Time frame: Up to Day 7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Humanpharmakologisches Zentrum Biberach
Biberach, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.